Related references
Note: Only part of the references are listed.Favorable Response to Erlotinib in a Lung Adenocarcinoma With Both Epidermal Growth Factor Receptor Exon 19 Deletion and K-ras G13D Mutations
Chun-Nin Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Gene Expression Signature Associated with K-Ras Addiction Reveals Regulators of EMT and Tumor Cell Survival
Anurag Singh et al.
CANCER CELL (2009)
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
David M. Jackman et al.
CLINICAL CANCER RESEARCH (2009)
EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery Impact on Outcome to Treatment with Gefitinib and Association with EGFR and KRAS Mutations in a Japanese Cohort
Marileila Varella-Garcia et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
Enriclueta Felip et al.
CLINICAL CANCER RESEARCH (2008)
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib
Vincent A. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21
Chang-Qi Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer An Analysis of Patients from German Centers in the TRUST Study
Claus-Peter Schneider et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents:: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
Helena Linardou et al.
LANCET ONCOLOGY (2008)
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03
G. D'Addario et al.
ANNALS OF ONCOLOGY (2008)
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Erminia Massarelli et al.
CLINICAL CANCER RESEARCH (2007)
The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer
Shuji Ichihara et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
N. van Zandwijk et al.
ANNALS OF ONCOLOGY (2007)
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib
F. R. Hirsch et al.
ANNALS OF ONCOLOGY (2007)
Phase II clinical trial of chemotherapy-naive patients >= 70 years of age treated with erlotinib for advanced non-small-cell lung cancer
David M. Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
Fred R. Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation
SW Han et al.
CLINICAL CANCER RESEARCH (2006)
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor
N Fujimoto et al.
CANCER RESEARCH (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
W Pao et al.
PLOS MEDICINE (2005)
Share Paper
